Ivosidenib is used as a drug for leukemia with specific mutations, and its use should be strictly followed by a doctor. The following is a detailed description of Ivosidenib, including indications, dosage, adverse reactions and precautions, to help patients better understand and use the drug.

Instruction manual for ivosideb

Ivosidenib (Tibsovo, Tosuvo, AG-120) is a specific leukemia treatment, and it is important for patients to understand the contents of the label.

Indications

Ivosidenib is indicated for the diagnosis of relapsed or refractory acute myeloid leukemia (AML) harboring a susceptible isocitrate dehydrogenase-1 (IDH1) mutation using a well-validated assay.

Dosage

The recommended dose is 500 mg orally once daily until disease progression or unacceptable toxicity. Treatment is required for at least 6 months to observe clinical response. The drug can be taken by mouth on an empty stomach or after meals, but high-fat meals should be avoided. If the dose is missed, it should be retaken as soon as possible, but if it is less than 12 hours before the next dose, there is no need to retake it.

Adverse effects

Common adverse reactions include fatigue, arthralgia, diarrhea, edema, nausea, etc. In addition, symptoms such as dyspnea, mucositis, and rash may occur. Patients should pay close attention to adverse reactions and report them to their doctor in a timely manner.

Medication precautions

Drug interactions

When Ivosidenib is used in combination with certain drugs, such as strong CYP3A4 inhibitors, the dose may need to be adjusted. At the same time, it should be avoided with drugs that prolong the QTc interval to prevent increased cardiac risk.

Monitoring and inspection

During treatment, blood counts, blood biochemistry, and electrocardiogram (ECG) should be done regularly to monitor drug effects and possible adverse effects. In particular, ECGs should be more frequent in the early stages of treatment.

Special populations

Ivosidenib should be used with caution and enhanced monitoring in patients with congenital long QTc syndrome, congestive heart failure, or electrolyte abnormalities, as well as those taking medications that may prolong the QTc interval.

Storage and safekeeping

Ivosidenib should be shaded, sealed, stored in a dry place, and the temperature should not exceed 25°C. Avoid moisture, heat, or direct sunlight to maintain drug stability and efficacy.

Ivosidenib is an effective treatment for specific IDH1-mutant leukemias. During use, patients should strictly follow the doctor's instructions, pay attention to the dosage, pay close attention to adverse reactions, and conduct relevant examinations regularly. Medications should be kept properly and a doctor should be consulted promptly if in case of any doubts or discomfort.